ArticleCell death & disease2015

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

G S Choudhary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.